

## Special Issue

# Advances in Tuberculosis: Comprehensive Insights and Management Strategies

### Message from the Guest Editor

Tuberculosis (TB), the leading cause of death from a curable infectious disease, remains a significant global health challenge. In 2022, 10.6 million people were diagnosed with TB, and 1.6 million TB-related deaths were reported. The COVID-19 pandemic has disrupted TB control programs, reversing recent progress.

However, significant scientific breakthroughs in TB prevention, screening, diagnostics, and treatment have emerged in the past decade, offering hope for better control and management. Recent advances include the use of highly sensitive diagnostic tools like the Xpert MTB/RIF Ultra, capable of the early detection of TB.

Shorter, all-oral treatment regimens for drug-susceptible (DS-TB) and drug-resistant TB (DR-TB), endorsed by the WHO, represent significant progress. Understanding the genetic and molecular mechanisms of both the host and *Mycobacteria* is crucial for advancing TB management strategies. This Special Issue explores comprehensive strategies for managing TB, including both pulmonary and extra-pulmonary forms. Key topics include innovative TB screening, prevention methods, and rapid diagnostics.

### Guest Editor

Dr. Aliaksandr Skrahin

Medical Expert, RCV Rare Disease GmbH, Berlin, Germany

### Deadline for manuscript submissions

20 January 2026



## Journal of Clinical Medicine

an Open Access Journal  
by MDPI

Impact Factor 2.9  
CiteScore 5.2  
Indexed in PubMed



[mdpi.com/si/210201](https://mdpi.com/si/210201)

*Journal of Clinical Medicine*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[jcm@mdpi.com](mailto:jcm@mdpi.com)

[mdpi.com/journal/](https://mdpi.com/journal/)

[jcm](https://jcm)





# Journal of Clinical Medicine

---

an Open Access Journal  
by MDPI

---

Impact Factor 2.9  
CiteScore 5.2  
Indexed in PubMed



[mdpi.com/journal/  
jcm](https://mdpi.com/journal/jcm)



## About the Journal

### Message from the Editorial Board

There has been an explosion of gene and target based research and therapeutics in the multitude of fields that compose clinical medicine. The *Journal of Clinical Medicine's* (JCM) staff and editorial board are dedicated to providing cutting edge, timely, and peer-reviewed articles covering the diverse subspecialties of clinical medicine. The journal publishes concise, innovative, and exciting research articles as well as clinically significant articles and reviews that are pertinent to the myriad of disciplines within medicine. The articles published are relevant to both primary care physicians and specialists. The journal's full-texts are archived in PubMed Central and indexed in PubMed. Please consider submitting your manuscripts for publication to our journal and check us out on-line!

---

### Editors-in-Chief

Prof. Dr. Emmanuel Andr  s

Internal Medicine Department, University Hospital Strasbourg, 67000  
Strasbourg, France

Prof. Dr. Kent Doi

Department of Acute Care Medicine, University of Tokyo, Tokyo, Japan

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q1  
(General Medicine)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.7 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the first half of 2025).